|
|
>Infektiosairaudet »
Medicine / Sisätaudit
Infectious diseases / Infektiosairaudet
Tällä sivulla näkyvät tutkimuksen perustiedot.
| TUTKIMUKSEN NIMI | Extraintestinal manifestation of Clostridium difficile Infections 17 years experience at a University hospital presentation of two bacteremia and review of the literature |
| Tutkimuksen yksilöivä numero | 230679 |
| Vastuuhenkilön nimi | Anttila Veli-Jukka |
| Vastuuhenkilön puhelin | +358 9 4711 |
| Vastuuhenkilön sähköposti | veli-jukka.anttila@hus.fi |
| Tutkimussairaala ja yksikkö | Helsinki University Central Hospital Department of Medicine Division of Infectious diseases |
| Aloituspäivämäärä | 2007-08-01 |
| Päättymispäivämäärä | 2008-12-31 |
| Tila | Ongoing / Tutkimus käynnissä |
| Tutkimuksen jaottelu | Clinical and Biomedical Research / Lääketieteellinen ja biolääketieteellinen tutkimus |
| Eettisen toimikunnan lausuntonumero | |
| Erikoisala | Medicine / Sisätaudit |
| Suppea erikoisala | Infectious diseases / Infektiosairaudet |
| Yhteistyötahot HUS:ssa | HUSLAB / HUSLAB |
| Yhteistyötahot muut | |
| Julkaisut ja tulokset |
Tutkimussuunnitelma:
In recent years the incidence and mortality of CDAD has increased worldwide. The objective of the study is to determine the clinical characteristics of patients with extraintestinal Clostridium difficile infection. All deep bacterial cultures of Clostridium difficile (approximately 20 patients) since 1990 in HUCH will be evaluated retrospectively. Two bacteremia will be described and literature reviewed.
http://www.hus.fi/?Path=1%3B28%3B2530%3B9899%3B9900
%3B9983%3B23554%3B24018
_____________________________________
| TUTKIMUKSEN NIMI | Finnish experience with Clostridium difficile ribotype O27 other strains mortality and severity of the disease and risk for relapse |
| Tutkimuksen yksilöivä numero | 232473 |
| Vastuuhenkilön nimi | Anttila Veli-Jukka |
| Vastuuhenkilön puhelin | +358 9 4711 |
| Vastuuhenkilön sähköposti | veli-jukka.anttila@hus.fi |
| Tutkimussairaala ja yksikkö | Helsinki University Central Hospital Department of Medicine Division of Infectious Diseases |
| Aloituspäivämäärä | 2008-06-02 |
| Päättymispäivämäärä | 2008-12-31 |
| Tila | Ongoing / Tutkimus käynnissä |
| Tutkimuksen jaottelu | Clinical and Biomedical Research / Lääketieteellinen ja biolääketieteellinen tutkimus |
| Eettisen toimikunnan lausuntonumero | |
| Erikoisala | Medicine / Sisätaudit |
| Suppea erikoisala | Infectious diseases / Infektiosairaudet |
| Yhteistyötahot HUS:ssa | No co-operation / Ei yhteistyötä HUS:ssa |
| Yhteistyötahot muut | |
| Julkaisut ja tulokset |
Tutkimussuunnitelma:
Helsinki region experience with Clostridium difficile ribotype O 27/
other strains: mortality and severity of the disease and risk for
relapse
There is no funding source of this study at the moment ( 2.5.08)
The primary sponsor is Helsinki University Central Hospital, Department of Medicine, Division of Infectious Diseases
Study type: retrospective epidemiological study
Purpose:To
compare severity, 30-day mortality and relapse of C. difficile disease
with 027 virulence factors versus C difficile disease without these
virulence factors. Patients will be stratified by McCabe and Jackson
for severity of underlying illness. Severe C. difficile disease is
defined as having one or more of shock, paralytic ileus,
pseudomembranous colitis, toxic megacolon or peripheral leukocyte count
> 15 000 cells/mL.
Diagnosis and main criteria for inclusion (target population):
Male
and female CDAD subjects, age 18 years and above with C difficile
infection in Helsiki region hospitals ( population 1.5 million )
11/07-5/08
Lisätietoja:
asiakirjatutkimus
http://www.hus.fi/default.asp?path=1,28,2530,9899,9900,9983,23554,23731
_____________________________________
| TUTKIMUKSEN NIMI | Influence of a new polycationic disinfectant on Clostridium difficile incidence and environmental colonisation |
| Tutkimuksen yksilöivä numero | 231109 |
| Vastuuhenkilön nimi | Kanerva Mari |
| Vastuuhenkilön puhelin | +358 9 4711 |
| Vastuuhenkilön sähköposti | mari.kanerva@hus.fi |
| Tutkimussairaala ja yksikkö | |
| Aloituspäivämäärä | 2007-10-15 |
| Päättymispäivämäärä | 2008-06-30 |
| Tila | Closed / Tutkimus päättynyt |
| Tutkimuksen jaottelu | Clinical and Biomedical Research / Lääketieteellinen ja biolääketieteellinen tutkimus |
| Eettisen toimikunnan lausuntonumero | 180/E0/07 |
| Erikoisala | Medicine / Sisätaudit |
| Suppea erikoisala | Infectious diseases / Infektiosairaudet |
| Yhteistyötahot HUS:ssa | Department of Surgery / Kirurgian tulosyksikkö,Support Sevice Central / Palvelukeskus |
| Yhteistyötahot muut | |
| Julkaisut ja tulokset |
Tutkimussuunnitelma:
Influence of a new polycationic disinfectant on Clostridium difficile incidence and environmental colonisation
The
study is funded by TEKES ( Finnish Funding Agency for Technology and
Innovation ) and Softcare Ltd. The primary sponsor is Helsinki
University Central Hospital, Department of Medicine, Division of
Infectious Diseases.
The aim of this study is to 1) test the
efficacy of PHMG-based disinfectant against C. difficile spores, 2)
test whether it reduces the incidence of C. difficile associated
disease (CDAD) and 3) evaluate cost.
New disinfectant will be
introduced in three wards for hand hygiene and environmental
disinfection in CDAD patients� rooms. It replaces alcohol based
disinfectant in study wards. Three wards will be control wards and
continue using alcohol based hand disinfectants and routine
environmental cleaning and disinfection with quats. The rooms for
showers and toilets will be coated with biocide coating as well as bed
frames.After 6 month�s intervention period, the incidence of CDAD cases
after will be compared to that during the preceeding 6 months.
Surveillance for environmental and HCWsŽ hand contamination by C.
difficile will be performed by taking microbiological samples both from
environmental sites and hands twice before intervention and then twice
in month within intervention period.
C. difficile cases will be
searched by active laboratory based surveillance. Each case will be
confirmed both by microbiological tests and clinically by infectious
diseases consultant (Eero Mattila) in all study wards. Patient records
will be studied for extra costs caused by infection. Prolongation of
hospitalization will be examinated by AEP (appropriateness evaluation
protocol) method by infectious diseases consultant (Eero Mattila) in
Meilahti wards. Cost of extra day is the average patient day cost in
HYKS. ./..
Lisätietoja:
./..
Unit costs of extra procedures and medication caused by C.
difficile infection will be examinated retrospectively from patients
records. Medication costs include both antibiotics to treat C.
difficile and medication used to complications due to infection. Also
medications prescribed to home use will be calculated. Isolation cost
will be included (if the patients are not isolated as recommended,
isolation costs will be approximated). Rehospitalization and visits to
policlinics will be counted if the reason for them is C. difficile
infection. Medication costs to patient will be counted but not the
opportunity costs for time.
http://www.hus.fi/default.asp?path=1,28,2530,9899,9900,9983,23554,24000
_____________________________________
_____________________________________